Abbonarsi

Development and Validation of a Model to Predict Neonatal Abstinence Syndrome - 21/01/21

Doi : 10.1016/j.jpeds.2020.10.030 
Stephen W. Patrick, MD, MPH, MSc 1, 2, 3, , James C. Slaughter, DrPH 4, Frank E. Harrell, PhD 4, Peter R. Martin, MD, MSc 5, 6, Katherine Hartmann, MD, PhD 7, Judith Dudley, BS 2, Shannon Stratton, BS 2, William O. Cooper, MD, MPH 1, 2
1 Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 
2 Department of Health Policy, Vanderbilt University Medical Center, Nashville, TN 
3 Mildred Stahlman Division of Neonatology, Vanderbilt University Medical Center, Nashville, TN 
4 Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 
5 Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN 
6 Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 
7 Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN 

Reprint requests: Stephen W. Patrick, MD, MPH, Vanderbilt Center for Child Health Policy, 2525 West End Ave, Suite 1200, Nashville, TN 37203Vanderbilt Center for Child Health Policy2525 West End AveSuite 1200NashvilleTN37203

Abstract

Objectives

To develop and validate clinical risk prediction tools for neonatal abstinence syndrome (NAS).

Study design

We developed prediction models for NAS based on a set of 30 demographic and antenatal exposure covariates collected during pregnancy. Data (outpatient prescription, vital, and administrative records), were obtained from enrollees in the Tennessee Medicaid Program from 2009 to 2014. Models were created using logistic regression and backward selection based on improvement in the Akaike information criterion, and internally validated using bootstrap cross-validation.

Results

A total of 218 020 maternal and infant dyads met inclusion criteria, of whom 3208 infants were diagnosed with NAS. The general population model included age, hepatitis C virus infection, days of opioid used by type, number of cigarettes used daily, and the following medications used in the last 30 day of pregnancy: bupropion, antinausea medicines, benzodiazepines, antipsychotics, and gabapentin. Infant characteristics included birthweight, small for gestational age, and infant sex. A high-risk model used a smaller number of predictive variables. Both models discriminated well with an area under the curve of 0.89 and were well-calibrated for low-risk infants.

Conclusions

We developed 2 predictive models for NAS based on demographics and antenatal exposure during the last 30 days of pregnancy that were able to risk stratify infants at risk of developing the syndrome.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : HCV, ICD-9-CM, MOUD, NAS


Mappa


 Supported by the National Institute on Drug Abuse of the National Institutes of Health under award number K23DA038720 (to S.P.) and by the Tennessee Department of Health (to S.P). F.H. was supported by Clinical and Translational Science Alliance award No. UL1 TR002243 from the National Center for Advancing Translational Sciences for his work on this paper. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the National Institute on Drug Abuse, the National Center for Advancing Translational Sciences or the National Institutes of Health. The authors declare no conflicts of interest.


© 2020  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 229

P. 154 - febbraio 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Epidemiology of Surgical Procedures, Anesthesia, and Imaging Studies by Gestational Age during the First Year of Life in Medicaid-Insured Infants
  • Andreas H. Taenzer, Reto M. Baertschiger, Cecilia Ganduglia Cazaban, Rebecca E. Evans, Megan Murphy, Jared Wasserman, David C. Goodman
| Articolo seguente Articolo seguente
  • Costs of Neonatal Intensive Care for Canadian Infants with Preterm Birth
  • Juan D. Rios, Prakesh S. Shah, Marc Beltempo, Deepak Louis, Amit Mukerji, Shahirose Premji, Vibhuti Shah, Shoo K. Lee, Petros Pechlivanoglou, Canadian Preterm Birth Network Investigators, the Canadian Neonatal Network Investigators, Haim Abenhaim, Jehier Afifi, Ruben Alvaro, James Andrews, Anthony Armson, Francois Audibert, Khalid Aziz, Marilyn Ballantyne, Jon Barrett, Anick Berard, Valerie Bertelle, Lucie Blais, Alan Bocking, Jaya Bodani, Jason Burrows, Kimberly Butt, Roderick Canning, George Carson, Nils Chaillet, Sue Chandra, Paige Church, Zenon Cieslak, Joan Crane, Dianne Creighton, Orlando Da Silva, Thierry Daboval, Leanne Dahlgren, Sibasis Daspal, Cecilia de Cabo, Akhil Deshpandey, Kimberly Dow, Christine Drolet, Michael Dunn, Darine El-Chaar, Walid El-Naggar, Carlos Fajardo, Robert Gagnon, Rob Gratton, Victor Han, Adele Harrison, Shabih Hasan, Michael Helewa, Matthew Hicks, K.S. Joseph, Andrzej Kajetanowicz, Zarin Kalapesi, May Khairy, Thierry Lacaze-Masmonteil, Kyong-Soon Lee, Brigitte Lemyre, Abhay Lodha, Thuy Mai Luu, Linh Ly, Annette Majnemer, Hala Makary, Isabelle Marc, Edith Masse, Sarah D. McDonald, Doug McMillan, Nir Melamed, Amy Metcalfe, Diane Moddemann, Luis Monterrosa, Michelle Morais, William Mundle, Lynn Murphy, Kellie Murphy, Anne-Monique Nuyt, Chuks Nwaesei, Karel O’Brien, Martin Offringa, Cecil Ojah, Annie Ouellet, Jean-Charles Pasquier, Ermelinda Pelausa, Bruno Piedboeuf, Elodie Portales-Casamar, Pramod Puligandla, Eleanor Pullenayegum, Amber Reichert, Kate Robson, Carol Schneider, Mary Seshia, Prakesh S. Shah, Rebecca Sherlock, Sandesh Shivananda, Nalini Singhal, Erik Skarsgard, Amanda Skoll, Graeme Smith, Anne Synnes, Katherine Thériault, Joseph Ting, Suzanne Tough, Jennifer Toye, Jagdeep Ubhi, Michael Vincer, Wendy Whittle, Hilary Whyte, Doug Wilson, Stephen Wood, Philip Ye, Wendy Yee, Jill Zwicker, Joseph Ting, Zenon Cieslak, Rebecca Sherlock, Ayman Abou Mehrem, Jennifer Toye, Carlos Fajardo, Zarin Kalapesi, Jaya Bodani, Koravangattu Sankaran, Sibasis Daspal, Mary Seshia, Ruben Alvaro, Orlando Da Silva, Mohammad Adie, Kyong-Soon Lee, Michael Dunn, Brigitte Lemyre, Faiza Khurshid, Ermelinda Pelausa, Keith Barrington, Anie Lapoint, Guillaume Ethier, Christine Drolet, Bruno Piedboeuf, Martine Claveau, Valerie Bertelle, Edith Masse, Roderick Canning, Hala Makary, Cecil Ojah, Luis Monterrosa, Julie Emberley, Jehier Afifi, Andrzej Kajetanowicz

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.